In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy

Triple negative breast cancer (TNBC) lack effective therapies. Here, through an in vivo genome-wide CRISPR screen in TNBCs, the authors identify tumorigenic functions for components of the mTORC1/2 complex and of the YAP/Hippo pathway, and demonstrate that pharmacological inhibition of mTOR and YAP...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Meiou Dai, Gang Yan, Ni Wang, Girija Daliah, Ashlin M. Edick, Sophie Poulet, Julien Boudreault, Suhad Ali, Sergio A. Burgos, Jean-Jacques Lebrun
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/38501aae84394eee911b035fc5797ebd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:38501aae84394eee911b035fc5797ebd
record_format	dspace
spelling	oai:doaj.org-article:38501aae84394eee911b035fc5797ebd2021-12-02T15:00:59ZIn vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy10.1038/s41467-021-23316-42041-1723https://doaj.org/article/38501aae84394eee911b035fc5797ebd2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-23316-4https://doaj.org/toc/2041-1723Triple negative breast cancer (TNBC) lack effective therapies. Here, through an in vivo genome-wide CRISPR screen in TNBCs, the authors identify tumorigenic functions for components of the mTORC1/2 complex and of the YAP/Hippo pathway, and demonstrate that pharmacological inhibition of mTOR and YAP reduces tumour growth in vivo.Meiou DaiGang YanNi WangGirija DaliahAshlin M. EdickSophie PouletJulien BoudreaultSuhad AliSergio A. BurgosJean-Jacques LebrunNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-18 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Meiou Dai Gang Yan Ni Wang Girija Daliah Ashlin M. Edick Sophie Poulet Julien Boudreault Suhad Ali Sergio A. Burgos Jean-Jacques Lebrun In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy
description	Triple negative breast cancer (TNBC) lack effective therapies. Here, through an in vivo genome-wide CRISPR screen in TNBCs, the authors identify tumorigenic functions for components of the mTORC1/2 complex and of the YAP/Hippo pathway, and demonstrate that pharmacological inhibition of mTOR and YAP reduces tumour growth in vivo.
format	article
author	Meiou Dai Gang Yan Ni Wang Girija Daliah Ashlin M. Edick Sophie Poulet Julien Boudreault Suhad Ali Sergio A. Burgos Jean-Jacques Lebrun
author_facet	Meiou Dai Gang Yan Ni Wang Girija Daliah Ashlin M. Edick Sophie Poulet Julien Boudreault Suhad Ali Sergio A. Burgos Jean-Jacques Lebrun
author_sort	Meiou Dai
title	In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy
title_short	In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy
title_full	In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy
title_fullStr	In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy
title_full_unstemmed	In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy
title_sort	in vivo genome-wide crispr screen reveals breast cancer vulnerabilities and synergistic mtor/hippo targeted combination therapy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/38501aae84394eee911b035fc5797ebd
work_keys_str_mv	AT meioudai invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT gangyan invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT niwang invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT girijadaliah invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT ashlinmedick invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT sophiepoulet invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT julienboudreault invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT suhadali invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT sergioaburgos invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT jeanjacqueslebrun invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy
_version_	1718389131169497088

In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy

Ejemplares similares